3-(bis(3-(N,N-dimethylamino)propyl)carbamoyl)propanoic acid | 1182800-65-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 3-(bis(3-(N,N-dimethylamino)propyl)carbamoyl)propanoic acid
• 英文别名: 4-[Bis[3-(dimethylamino)propyl]amino]-4-oxobutanoic acid
• CAS: 1182800-65-2
• 化学式: C₁₄H₂₉N₃O₃
• 分子量: 287.403
• InChiKey: CZECJQINNLHXKD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.3
• 重原子数：
  20
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  64.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-碘十二烷 、 3-(bis(3-(N,N-dimethylamino)propyl)carbamoyl)propanoic acid 在 Amberlite IRA-400(Cl) 作用下， 以 N,N-二甲基甲酰胺 、 水 为溶剂， 反应 13.0h， 以100%的产率得到[3-(bis(3-(N-dodecyl-N,N-dimethylamino)propyl)carbamoyl)propanoic acid] dichloride
  参考文献：
  名称：

  Drug delivery agents comprising cyclodextrin covalently linked to a gemini surfactant, and pharmaceutical compositions comprising the same

  摘要：

  这份披露涉及到基于环糊精的药物传递剂，其中包括一个环糊精基团与一种双胺基表面活性剂基团共价连接的药物传递剂。还披露了包括该药物传递剂和治疗剂的药物组合物。

  公开号：

  US09168306B2
• 作为产物：
  描述：

  丁二酸酐 、 3,3′-亚氨基双(N,N-二甲基丙胺) 以 N,N-二甲基甲酰胺 为溶剂， 反应 72.0h， 以100%的产率得到3-(bis(3-(N,N-dimethylamino)propyl)carbamoyl)propanoic acid
  参考文献：
  名称：

  Drug delivery agents comprising cyclodextrin covalently linked to a gemini surfactant, and pharmaceutical compositions comprising the same

  摘要：

  这份披露涉及到基于环糊精的药物传递剂，其中包括一个环糊精基团与一种双胺基表面活性剂基团共价连接的药物传递剂。还披露了包括该药物传递剂和治疗剂的药物组合物。

  公开号：

  US09168306B2

文献信息

• Amine salts for use in gasoline engines
  申请人：The Lubrizol Corporation

  公开号：US11208603B2

  公开（公告）日：2021-12-28

  Fuel compositions comprising at least 10 ppm by weight of a succinic ester acid amine salt or a succinamide acid amine salt (both “amine salt(s)”). The amine salt is the product of (a) and (b), wherein: (a) is an amine with (i) at least one tertiary nitrogen and (ii) at least one hydroxy alkyl functional group and/or at least one secondary amine functionality; and (b) is a hydrocarbyl-substituted succinic acid/or anhydride. The molar ratio of (a) to (b) may range from 3:1 to 1:3. The fuel composition may comprise gasoline, oxygenate, or mixtures thereof. Methods and uses for reducing carbonaceous deposits in an engine comprising operating the engine using the fuel composition having an amine salt therein.

  包含至少 10 ppm（重量）的琥珀酸酯酸胺盐或琥珀酰胺酸胺盐（均为 "胺盐"）的燃料组合物。胺盐是(a)和(b)的产物，其中(a)是具有(i)至少一个叔氮和(ii)至少一个羟基烷基官能团和/或至少一个仲胺官能团的胺；(b)是烃基取代的琥珀酸/或酸酐。(a)与(b)的摩尔比可从 3:1 到 1:3。燃料组合物可包括汽油、含氧化合物或其混合物。减少发动机中碳沉积物的方法和用途，包括使用含有胺盐的燃料组合物操作发动机。
• Design and evaluation of cyclodextrin-based delivery systems to incorporate poorly soluble curcumin analogs for the treatment of melanoma
  作者：Deborah Michel、Jackson M. Chitanda、Réka Balogh、Peng Yang、Jagbir Singh、Umashankar Das、Anas El-Aneed、Jonathan Dimmock、Ronald Verrall、Ildiko Badea

  DOI：10.1016/j.ejpb.2012.03.016

  日期：2012.8

  Various analogs of curcumin show high in vitro cytotoxic activity and are potential candidates for treating a deadly skin disease, melanoma. Due to the low solubility of the drugs, a new delivery agent, namely a cationic gemini surfactant-conjugated B-cyclodextrin, was designed to incorporate novel drug candidates of the 1,5-diaryl-3-oxo-1,4-pentadienyl family. Based on physicochemical parameters, such as particle size and zeta potential, a schematic model for the potential interaction of the drug with the delivery agent was developed. The drug formulations were highly efficient in inhibiting the growth of melanoma cells, with IC50 values significantly lower than melphalan, the drug currently used for the treatment of in-transit melanoma. CDgemini formulations showed excellent cellular selectivity, triggering apoptosis in the A375 cell line while showing no cytotoxicity to healthy human epidermal keratinocytes. The goal is to develop this novel nanoparticle approach into a non-invasive therapy for in-transit melanoma metastasis that lacks adequate treatment to date. (C) 2012 Elsevier B.V. All rights reserved.
• DRUG DELIVERY AGENTS COMPRISING CYCLODEXTRIN COVALENTLY LINKED TO A GEMINI SURFACTANT, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
  申请人：Badea Ildiko

  公开号：US20140113977A1

  公开（公告）日：2014-04-24

  This disclosure relates to cyclodextrin-based drug delivery agents that comprise a cyclodextrin moiety covalently linked to a moiety of a gemini surfactant. Pharmaceutical compositions comprising the drug delivery agent and a therapeutic agent are also disclosed.
• AMINE SALTS FOR USE IN GASOLINE ENGINES
  申请人：The Lubrizol Corporation

  公开号：US20200255756A1

  公开（公告）日：2020-08-13

  Fuel compositions comprising at least 10 ppm by weight of a succinic ester acid amine salt or a succinamide acid amine salt (both “amine salt(s)”). The amine salt is the product of (a) and (b), wherein: (a) is an amine with (i) at least one tertiary nitrogen and (ii) at least one hydroxy alkyl functional group and/or at least one secondary amine functionality; and (b) is a hydrocarbyl-substituted succinic acid/or anhydride. The molar ratio of (a) to (b) may range from 3:1 to 1:3. The fuel composition may comprise gasoline, oxygenate, or mixtures thereof. Methods and uses for reducing carbonaceous deposits in an engine comprising operating the engine using the fuel composition having an amine salt therein.
• FUEL ADDITIVE COMPOSITIONS FOR GASOLINE DIRECT INJECTION ENGINES
  申请人：The Lubrizol Corporation

  公开号：US20220411705A1

  公开（公告）日：2022-12-29

  Methods of reducing stochastic pre-ignition events and/or carbonaceous deposits in a gasoline-fueled engine by adding at least 10 ppm by weight of a compound having at least one alkyl succinic acid group to a gasoline fuel, wherein said compound is the product of (a) and (b), wherein: (a) is an amine with at least one tertiary nitrogen, water, or a hydrocarbyl substituted alcohol; and (b) is a hydrocarbyl-substituted succinic acid and/or anhydride.